News
News from us and our partners
Tags
Topics
0 results
- News
Bionyra Pharma announces first healthy volunteers dosed in Phase 1 study of BYN-001, a long-acting IL-25 antibody for atopic dermatitis
- News
NodThera changes name to Rezera Inc. and announces Ruvonoflast Phase 3 development program
- News
ProQR announces first participant dosed in Phase 1 study of AX-0811
- News
Rezera announces Ruvonoflast met primary inflammation endpoint and demonstrated favorable safety profile in trial
- News
Neurent Medical secures €25 million growth debt facility from Claret Capital Partners to accelerate commercial expansion
- News
Mainstay Medical announces two-year outcomes from RESTORE clinical trial of ReActiv8®
- News
Sensorion announces approval of clinical trial application in France for SENS-601 gene therapy for GJB2-related hearing loss
- News
Biotalys secures product registration in California for EVOCA®, strengthening regulatory pathway for lead asset
- News
Inventiva announces last patient visit in NATiV3 Phase 3 clinical trial of Lanifibranor in MASH
- News
Medtronic announces strategic investment in Pi-Cardia to accelerate innovation for complex TAVR
- News
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer
- News
Inventiva appoints Chris Benecchi as Chief Operating Officer
- News
Lupin and Tenpoint Therapeutics announce strategic partnership to commercialize YUVEZZI
- News
Galvanize Therapeutics® announces latest exploratory evidence suggesting immune-activating potential of Aliya® PEF Energy
- News
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies